Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Jörg Petersen & Maria Buti. (2012) Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Expert Review of Gastroenterology & Hepatology 6:6, pages 683-694.
Read now
Read now
Giorgio L Colombo, Giovanni B Gaeta, Mauro Viganò & Sergio Di Matteo. (2011) A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. ClinicoEconomics and Outcomes Research 3, pages 37-46.
Read now
Read now
Natravis Cox & Hans Tillmann. (2011) Emerging pipeline drugs for hepatitis B infection. Expert Opinion on Emerging Drugs 16:4, pages 713-729.
Read now
Read now
Alice M Jenh & Paul A Pham. (2010) Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Review of Anti-infective Therapy 8:10, pages 1079-1092.
Read now
Read now
Articles from other publishers (25)
Brandon Havranek, Robel Demissie, Hyun Lee, Shuiyun Lan, Huanchun Zhang, Stefanos Sarafianos, Anoklase Jean-Luc Ayitou & Shahidul M. Islam. (2023) Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach. Journal of Chemical Information and Modeling 63:22, pages 7180-7188.
Crossref
Crossref
Mahadevabharath R. Somayaji, Debarun Das, Harsha Teja Garimella, Carrie L. German, Andrzej J. Przekwas & Laurent Simon. (2021) An integrated biophysical model for predicting the clinical pharmacokinetics of transdermally delivered compounds. European Journal of Pharmaceutical Sciences 167, pages 105924.
Crossref
Crossref
Matilde Hoffman, DeGaulle I. Chigbu, Brenndan L. Crumley, Ravi Sharma, Sergey Pustylnikov, Thomas Crilley, Rashida Ginwala, Ronak Loonawat, Julie Joseph, Dominic Sales, Sydney Wilson & Pooja Jain. 2020. Advanced Concepts in Human Immunology: Prospects for Disease Control. Advanced Concepts in Human Immunology: Prospects for Disease Control
1
120
.
Vural Taner Yilmaz, Ramazan Cetinkaya, Halide Akbas, Sebahat Ozdem, Burak Veli Ulger, Halil Erbis, Mehmet Bakirtas, İbrahim Aliosmanoglu, Gultekin Suleymanlar, Dilek Colak & Huseyin Kocak. (2019) Comparison of Clinical Outcomes in Hepatitis B Virus–Positive and –Negative Renal Transplant Recipients. International Surgery 104:9-10, pages 423-430.
Crossref
Crossref
Quan Zhang, Junhao Chen, Mingjie Pan, Jingli Liu, Tingting Liu & Yi-Hua Zhou. (2018) Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient. Virus Research 255, pages 165-170.
Crossref
Crossref
Luděk Eyer, Radim Nencka, Erik de Clercq, Katherine Seley-Radtke & Daniel Růžek. (2018) Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses. Antiviral Chemistry and Chemotherapy 26, pages 204020661876129.
Crossref
Crossref
Yu-Fang Chen, Chin-Liew Chong, Yi-Chieh Wu, Yi-Ling Wang, Kuen-Nan Tsai, Tzer-Min Kuo, Ming-Hsiang Hong, Cheng-po Hu, Mong-Liang Chen, Yu-Chi Chou & Chungming Chang. (2015) Doxorubicin Activates Hepatitis B Virus Replication by Elevation of p21 (Waf1/Cip1) and C/EBPα Expression. PLOS ONE 10:6, pages e0131743.
Crossref
Crossref
Daniela Bertacchi, Fabio Zucca, Sergio Foresti, Davide Mangioni & Andrea Gori. (2014) Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach. Mathematical Medicine and Biology, pages dqu022.
Crossref
Crossref
Marcelo S. Sampaio, Paul Martin & Suphamai Bunnapradist. (2014) Renal Dysfunction in End-Stage Liver Disease and Post–Liver Transplant. Clinics in Liver Disease 18:3, pages 543-560.
Crossref
Crossref
Merel M. Heuft, Sanne M. Houba, Guido E.L. van den Berk, Tessa Smissaert van de Haere, Alje P. van Dam, Lea M. Dijksman, Rosa M. Regez & Kees Brinkman. (2014) Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection. AIDS 28:7, pages 999-1005.
Crossref
Crossref
Fernando Cobo. 2014. Imported Infectious Diseases. Imported Infectious Diseases
213
225
.
Rui Huang, Yingying Hao, Jun Zhang & Chao Wu. (2013) Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis. Hepatology Research, pages n/a-n/a.
Crossref
Crossref
Xiu-Li Chen, Man Li & Xiao-Lan Zhang. (2013) HBV Genotype B/C and Response to Lamivudine Therapy: A Systematic Review. BioMed Research International 2013, pages 1-6.
Crossref
Crossref
Guoqing Zang. (2012) Intracellular-delivery of a single-chain antibody against hepatitis B core protein via cell-penetrating peptide inhibits hepatitis B virus replication in vitro. International Journal of Molecular Medicine.
Crossref
Crossref
Neeraj Shakya, Satish Vedi, Chao Liang, Babita Agrawal, D. Lorne Tyrrell & Rakesh Kumar. (2012) A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses. Bioorganic & Medicinal Chemistry Letters 22:20, pages 6475-6480.
Crossref
Crossref
Ryota Sueki, Shinya Maekawa, Mika Miura, Makoto Kadokura, Kazuki Komase, Hiroko Shindo, Asuka Kanayama, Takako Ohmori, Kuniaki Shindo, Fumitake Amemiya, Yasuhiro Nakayama, Tomoyoshi Uetake, Taisuke Inoue, Minoru Sakamoto & Nobuyuki Enomoto. (2012) Correlation between pretreatment viral sequences and the emergence of lamivudine resistance in hepatitis B virus infection. Journal of Medical Virology 84:9, pages 1360-1368.
Crossref
Crossref
Carmen Hidalgo-Tenorio, Mar Rivero, Marta Alvarez & Federico García. (2012) Resistencia del virus de la hepatitis B al entecavir. Medicina Clínica 139:5, pages 228-229.
Crossref
Crossref
Suk Jin HongByung-Ho Choe. (2012) Strategy to Overcome Drug Resistance That Develops during Treatment of Chronic Hepatitis B in Children. Pediatric Gastroenterology, Hepatology & Nutrition 15:2, pages 63.
Crossref
Crossref
. (2012) KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clinical and Molecular Hepatology 18:2, pages 109.
Crossref
Crossref
Zhao Wang, Xiao-Ling Wu, Wei-Zheng Zeng, Hui Xu, Yong Zhang, Jian-Ping Qin & Ming-De Jiang. (2011) Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment. Virology Journal 8:1.
Crossref
Crossref
E. J. Aspinall, G. Hawkins, A. Fraser, S. J. Hutchinson & D. Goldberg. (2011) Hepatitis B prevention, diagnosis, treatment and care: a review. Occupational Medicine 61:8, pages 531-540.
Crossref
Crossref
Pavani Naini Reddy, Marcelo Santos Sampaio, Hung-Tien Kuo, Paul Martin & Suphamai Bunnapradist. (2011) Impact of Pre-Existing Hepatitis B Infection on the Outcomes of Kidney Transplant Recipients in the United States. Clinical Journal of the American Society of Nephrology 6:6, pages 1481-1487.
Crossref
Crossref
Zhao Pan, Xu Dongping, Wang Xi, Duan Guangfeng & Huang Lili. (2010) Efficacy compared between entecavir and adefovir dipivoxil on HBeAg-positive nucleos(t)ide-naive patients with chronic hepatitis B at week 12 and week 48. Journal of Medical Colleges of PLA 25:5, pages 298-306.
Crossref
Crossref
Angela Rago, Miriam Lichtner, Sergio Mecarocci, Raffaella Marocco, Natalia Cenfra, Valeria Belvisi, Cosmo Del Borgo, Giuseppe Cimino & Claudio M Mastroianni. (2010) Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen. Antiviral Therapy 15:6, pages 929-932.
Crossref
Crossref
L. Martin-Carbonero & V. Soriano. (2010) New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. Journal of Antimicrobial Chemotherapy 65:3, pages 379-382.
Crossref
Crossref